Taysha Gene Therapies, Inc. Noncash or Part Noncash Acquisition, Fixed Assets Acquired
Taysha Gene Therapies, Inc. (TSHA) reported Noncash or Part Noncash Acquisition, Fixed Assets Acquired of $606.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 · last filed 2023-03-28
- Taysha Gene Therapies, Inc. noncash or part noncash acquisition, fixed assets acquired for the quarter ending 2021-12-31 was $0.00.
- Taysha Gene Therapies, Inc. noncash or part noncash acquisition, fixed assets acquired for the quarter ending 2021-09-30 was $0.00.
- Taysha Gene Therapies, Inc. noncash or part noncash acquisition, fixed assets acquired for the quarter ending 2021-06-30 was -$1.00K.
- Taysha Gene Therapies, Inc. noncash or part noncash acquisition, fixed assets acquired for the quarter ending 2021-03-31 was $607.00K.
- Taysha Gene Therapies, Inc. noncash or part noncash acquisition, fixed assets acquired for fiscal 2021 was $606.00K.
| Period end | Noncash or Part Noncash Acquisition, Fixed Assets Acquired 3 month | Noncash or Part Noncash Acquisition, Fixed Assets Acquired 6 month | Noncash or Part Noncash Acquisition, Fixed Assets Acquired 9 month | Noncash or Part Noncash Acquisition, Fixed Assets Acquired 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $0.00 derived: sum of 2 quarters · filed 2023-03-28 | -$1.00K derived: sum of 3 quarters · filed 2023-03-28 | $606.00K 10-K · filed 2023-03-28 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$1.00K derived: sum of 2 quarters · filed 2022-11-08 | $606.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $606.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $607.00K 10-Q · filed 2022-05-16 | |||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |